Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines
Abstract The primary immunological readout for clinical trials of R21/MatrixM™ malaria vaccine, is total IgG antibody specific to the central four amino acid NANP repeat region of the circumsporozoite protein. A multiplexed assay, which includes NANP, was developed and validated for four antigens re...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-01039-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586085009457152 |
|---|---|
| author | L. K. Stockdale S. Provstgaard-Morys D. Bellamy D. Woods K. Rapi A. Bajer B. Hollingdale O. Muñoz S. Malik A. V. S. Hill K. J. Ewer |
| author_facet | L. K. Stockdale S. Provstgaard-Morys D. Bellamy D. Woods K. Rapi A. Bajer B. Hollingdale O. Muñoz S. Malik A. V. S. Hill K. J. Ewer |
| author_sort | L. K. Stockdale |
| collection | DOAJ |
| description | Abstract The primary immunological readout for clinical trials of R21/MatrixM™ malaria vaccine, is total IgG antibody specific to the central four amino acid NANP repeat region of the circumsporozoite protein. A multiplexed assay, which includes NANP, was developed and validated for four antigens representing components of the R21 immunogen. Initial assay optimisation included validation of the HBsAg international standard. Further validation performed in Oxford covered intra and inter-assay, and inter-operator variability, accuracy of QC and standard curve material, and included bridging to a singleplex NANP6 ELISA. The assay was shown to be robust and specific, with a broad dynamic range. We report a strong linear relationship between NANP6 IgG as measured by the singleplex ELISA and the multiplexed assay with rho values of 0.89 and 0.88 for two separate clinical trials (both p < 0.0005). This assay can be used to measure antibodies specific to the CSP NANP repeat region, CSP C-term region, full length R21 and HBsAg. |
| format | Article |
| id | doaj-art-c194789ff02a4fa68212078dc58ea01c |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-c194789ff02a4fa68212078dc58ea01c2025-01-26T12:14:10ZengNature Portfolionpj Vaccines2059-01052025-01-0110111510.1038/s41541-024-01039-zValidation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccinesL. K. Stockdale0S. Provstgaard-Morys1D. Bellamy2D. Woods3K. Rapi4A. Bajer5B. Hollingdale6O. Muñoz7S. Malik8A. V. S. Hill9K. J. Ewer10Jenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreJenner Institute, University of Oxford, and the NIHR Oxford Biomedical Research CentreAbstract The primary immunological readout for clinical trials of R21/MatrixM™ malaria vaccine, is total IgG antibody specific to the central four amino acid NANP repeat region of the circumsporozoite protein. A multiplexed assay, which includes NANP, was developed and validated for four antigens representing components of the R21 immunogen. Initial assay optimisation included validation of the HBsAg international standard. Further validation performed in Oxford covered intra and inter-assay, and inter-operator variability, accuracy of QC and standard curve material, and included bridging to a singleplex NANP6 ELISA. The assay was shown to be robust and specific, with a broad dynamic range. We report a strong linear relationship between NANP6 IgG as measured by the singleplex ELISA and the multiplexed assay with rho values of 0.89 and 0.88 for two separate clinical trials (both p < 0.0005). This assay can be used to measure antibodies specific to the CSP NANP repeat region, CSP C-term region, full length R21 and HBsAg.https://doi.org/10.1038/s41541-024-01039-z |
| spellingShingle | L. K. Stockdale S. Provstgaard-Morys D. Bellamy D. Woods K. Rapi A. Bajer B. Hollingdale O. Muñoz S. Malik A. V. S. Hill K. J. Ewer Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines npj Vaccines |
| title | Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines |
| title_full | Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines |
| title_fullStr | Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines |
| title_full_unstemmed | Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines |
| title_short | Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines |
| title_sort | validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines |
| url | https://doi.org/10.1038/s41541-024-01039-z |
| work_keys_str_mv | AT lkstockdale validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT sprovstgaardmorys validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT dbellamy validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT dwoods validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT krapi validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT abajer validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT bhollingdale validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT omunoz validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT smalik validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT avshill validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines AT kjewer validationofamultiplexedimmunoassayforimmunologicalanalysisofpreerythrocyticmalariavaccines |